An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
PDQ Cancer Information Summaries [Internet].
Bethesda (MD): National Cancer Institute (US); 2002-.
Top results in this bookTable of Contents
Brain tumours (primary) and brain metastases in adults.
London: National Institute for Health and Care Excellence (NICE); 2021 Jan 29. (NICE Guideline, No. 99.)
Urinary Incontinence in Neurological Disease: Management of Lower Urinary Tract Dysfunction in Neurological Disease.
National Clinical Guideline Centre (UK).
London: Royal College of Physicians (UK); 2012 Aug. (NICE Clinical Guidelines, No. 148.)
Diagnosis and Management of Metastatic Malignant Disease of Unknown Primary Origin.
Cardiff (UK): National Collaborating Centre for Cancer (UK); 2010 Jul. (NICE Clinical Guidelines, No. 104.)
Suspected neurological conditions: recognition and referral.
National Guideline Centre (UK).
London: National Institute for Health and Care Excellence (NICE); 2019 May. (NICE Guideline, No. 127.)
Cerebral palsy in under 25s: assessment and management.
National Guideline Alliance (UK).
London: National Institute for Health and Care Excellence (NICE); 2017 Jan. (NICE Guideline, No. 62.)
Improving Palliative Care for Cancer: Summary and Recommendations.
Institute of Medicine (US) and National Research Council (US) National Cancer Policy Board; Foley KM, Gelband H, editors.
Washington (DC): National Academies Press (US); 2001.
WHO Guidelines for the Pharmacological and Radiotherapeutic Management of Cancer Pain in Adults and Adolescents.
Geneva: World Health Organization; 2018.
Non-Hodgkin's Lymphoma: Diagnosis and Management.
London: National Institute for Health and Care Excellence (NICE); 2016 Jul. (NICE Guideline, No. 52.)
Comprehensive Primary Care for Adults With HIV [Internet].
Dyer M, Kerr C, Fine SM, et al.
Baltimore (MD): Johns Hopkins University; 2022 Dec.
Mecasermin (Increlex): CADTH Reimbursement Recommendation: Indication: For the treatment of growth failure in children and adolescents from 2 to 18 years with confirmed severe primary insulin-like growth factor-1 deficiency [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Feb.
Substance Abuse Treatment for Persons With HIV/AIDS [Internet].
Rockville (MD): Substance Abuse and Mental Health Services Administration (US); 2000. (Treatment Improvement Protocol (TIP) Series, No. 37.)
Coeliac Disease: Recognition, Assessment and Management.
London: National Institute for Health and Care Excellence (NICE); 2015 Sep. (NICE Guideline, No. 20.)
Nelarabine (Atriance): CADTH Reimbursement Recommendation: Indication: Nelarabine (Atriance) for addition to front-line multiagent therapy of pediatric, adolescent, and young adult patients (aged 1 year to 30 years at diagnosis) with intermediate- or high-risk T-cell acute lymphoblastic leukemia [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 Oct.
Brolucizumab (Beovu): CADTH Reimbursement Review: Therapeutic area: Diabetic macular edema [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 Mar.
Pembrolizumab (Keytruda): CADTH Reimbursement Review: Therapeutic area: Triple-negative breast cancer [Internet].
WHO Guidelines for Indoor Air Quality: Selected Pollutants.
Geneva: World Health Organization; 2010.
Addendum to Clinical Guideline 81, Advanced Breast Cancer.
London: National Institute for Health and Care Excellence (NICE); 2017 Aug. (Clinical Guideline Addendum, No. 81.2.)
Practical Approaches to Managing Advanced Kidney Cancer: Version 2020 [Internet].
Rendon R, Kapoor A, authors; Heng DYC, Kollmannsberger C, editors.
Dorval (QC): Canadian Urological Association; 2020.
Trifluridine-Tipiracil (Lonsurf): CADTH Reimbursement Recommendation: Indication: In combination with bevacizumab, for the treatment of adult patients with metastatic colorectal cancer who have previously been treated with, or are not candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF biological agents, and, if RAS wild-type, anti-EGFR agents [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Mar.
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on